| 53.83 -1.37 (-2.48%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 69.96 | 1-year : | 81.71 |
| Resists | First : | 59.9 | Second : | 69.96 |
| Pivot price | 54.53  |
|||
| Supports | First : | 50.86 |
Second : | 45.27 |
| MAs | MA(5) : | 54.87 |
MA(20) : | 53.38 |
| MA(100) : | 45.93 |
MA(250) : | 54.95 |
|
| MACD | MACD : | 1.8 |
Signal : | 2 |
| %K %D | K(14,3) : | 51 |
D(3) : | 54.7 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 71.84 | Low : | 36.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NARI ] has closed above bottom band by 41.0%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 56.16 - 56.51 | 56.51 - 56.76 |
| Low: | 52.95 - 53.38 | 53.38 - 53.69 |
| Close: | 53.27 - 53.89 | 53.89 - 54.34 |
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Fri, 26 Jul 2024
Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)? - Yahoo Finance
Thu, 25 Jul 2024
Ameritas Investment Partners Inc. Has $266,000 Holdings in Inari Medical, Inc. (NASDAQ:NARI) - MarketBeat
Thu, 25 Jul 2024
Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes Sells 3,000 Shares - Defense World
Thu, 25 Jul 2024
Inari Medical CEO Andrew Hykes sells shares worth $165,690 - Investing.com
Tue, 23 Jul 2024
ProShare Advisors LLC Purchases 553 Shares of Inari Medical, Inc. (NASDAQ:NARI) - Defense World
Tue, 23 Jul 2024
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 58 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 9.1 (%) |
| Held by Institutions | 102.4 (%) |
| Shares Short | 4,660 (K) |
| Shares Short P.Month | 4,480 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.71 |
| Profit Margin | -4.6 % |
| Operating Margin | -5.7 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | -5.5 % |
| Qtrly Rev. Growth | 23.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.95 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 47 (M) |
| PE Ratio | -131.3 |
| PEG Ratio | -1.2 |
| Price to Book value | 6.98 |
| Price to Sales | 6.01 |
| Price to Cash Flow | 122.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|